Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone949-481-9825
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.08 million
Profitability
Miscellaneous
Employees4
Next Earnings DateN/A
OptionableNot Optionable
Aeolus Pharmaceuticals (OTCMKTS:AOLS) Frequently Asked Questions
What is Aeolus Pharmaceuticals' stock symbol?
Aeolus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "AOLS."
How were Aeolus Pharmaceuticals' earnings last quarter?
Aeolus Pharmaceuticals, Inc. (OTCMKTS:AOLS) announced its quarterly earnings results on Monday, August, 14th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter. The biopharmaceutical company had revenue of $0.01 million for the quarter. View Aeolus Pharmaceuticals' Earnings History.
Has Aeolus Pharmaceuticals been receiving favorable news coverage?
Press coverage about AOLS stock has trended somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aeolus Pharmaceuticals earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future.
Who are some of Aeolus Pharmaceuticals' key competitors?
Some companies that are related to Aeolus Pharmaceuticals include Mabvax Therapeutics (MBVX), Pernix Therapeutics (PTX), GlobeImmune (GBIM), Argos Therapeutics (ARGSQ), Myrexis (MYRX), Affymax (AFFY), Skinvisible (SKVI), Biostar Pharmaceuticals (BSPM), Spotlight Innovation (STLT), HST Global (HSTC), Tianyin Pharmaceutical (TPIY), Targeted Medical Pharma (TRGM), Orexigen Therapeutics (OREXQ), Immune Pharmaceuticals (IMNP) and Poniard Pharmaceuticals (PARD).
What other stocks do shareholders of Aeolus Pharmaceuticals own?
Who are Aeolus Pharmaceuticals' key executives?
Aeolus Pharmaceuticals' management team includes the folowing people:
- Mr. David C. Cavalier, Chairman, CFO & Sec. (Age 50)
- Mr. John L. Mcmanus, Chief Exec. Officer and Pres (Age 55)
- Mr. Christopher Stanley, VP of Operations
How do I buy shares of Aeolus Pharmaceuticals?
Shares of AOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aeolus Pharmaceuticals' stock price today?
One share of AOLS stock can currently be purchased for approximately $0.0024.
How big of a company is Aeolus Pharmaceuticals?
Aeolus Pharmaceuticals has a market capitalization of $365,016.00 and generates $2.08 million in revenue each year. Aeolus Pharmaceuticals employs 4 workers across the globe.
What is Aeolus Pharmaceuticals' official website?
How can I contact Aeolus Pharmaceuticals?
Aeolus Pharmaceuticals' mailing address is 26361 CROWN VALLEY PARKWAY SUITE 150, MISSION VIEJO CA, 92691. The biopharmaceutical company can be reached via phone at 949-481-9825 or via email at [email protected]
MarketBeat Community Rating for Aeolus Pharmaceuticals (OTCMKTS AOLS)
MarketBeat's community ratings are surveys of what our community members think about Aeolus Pharmaceuticals and other stocks. Vote "Outperform" if you believe AOLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AOLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
